FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377695014> ?p ?o ?g. }

• W4377695014 endingPage "113" @default.
• W4377695014 startingPage "105" @default.
• W4377695014 abstract "Objective To evaluate trends and racial variations of pathologic complete response (CR) in patients with muscle-invasive bladder cancer undergoing cystectomy. Materials and Methods The National Cancer Database was queried for patients with non-metastatic muscle-invasive bladder cancer who underwent neoadjuvant chemotherapy and surgery. The primary endpoints, CR and mortality, were evaluated using the Cochran-Armitage test, multivariable regression, and Kaplan-Meier analyses. Results The cohort comprised 9955 patients. Non-Hispanic Black (NHB) patients were younger (P < .001), had a higher clinical tumor (P < .001), and had higher clinical node (P = .029) stages at presentation. CR for non-Hispanic White (NHW), NHB, and Hispanic patients were 12.6%, 10.1%, and 11.8%, respectively (P = .030). There was a significant increase in CR trends for NHW patients (P < .001) and increases in NHB (P = .311) and Hispanic patients (P = .236). On multivariable analysis, NHW females had lower odds of achieving CR (odds ratio: 0.83, 95% CI: 0.71-0.97); however, NHB males (hazard ratio: 1.21, 1.01-1.44) and NHB females (hazard ratio: 1.25, 1.03-1.53) had higher overall mortality in adjusted analysis. Survival differences were not observed in patients who achieved CR, regardless of racial background; however, for those with residual disease, the 2-year survival probabilities were 60.7%, 62.5%, and 51.1% for NHW, HW, and NHB patients, respectively (log-rank P = .010). Conclusion Our findings revealed differences in chemotherapy response based on gender and race or ethnicity. The CR trends for all racial or ethnic groups increased over time. However, Black patients were found to have worse survival, particularly when residual disease was present. Clinical studies with more underrepresented minorities are needed to verify biological differences in response to neoadjuvant chemotherapy. To evaluate trends and racial variations of pathologic complete response (CR) in patients with muscle-invasive bladder cancer undergoing cystectomy. The National Cancer Database was queried for patients with non-metastatic muscle-invasive bladder cancer who underwent neoadjuvant chemotherapy and surgery. The primary endpoints, CR and mortality, were evaluated using the Cochran-Armitage test, multivariable regression, and Kaplan-Meier analyses. The cohort comprised 9955 patients. Non-Hispanic Black (NHB) patients were younger (P < .001), had a higher clinical tumor (P < .001), and had higher clinical node (P = .029) stages at presentation. CR for non-Hispanic White (NHW), NHB, and Hispanic patients were 12.6%, 10.1%, and 11.8%, respectively (P = .030). There was a significant increase in CR trends for NHW patients (P < .001) and increases in NHB (P = .311) and Hispanic patients (P = .236). On multivariable analysis, NHW females had lower odds of achieving CR (odds ratio: 0.83, 95% CI: 0.71-0.97); however, NHB males (hazard ratio: 1.21, 1.01-1.44) and NHB females (hazard ratio: 1.25, 1.03-1.53) had higher overall mortality in adjusted analysis. Survival differences were not observed in patients who achieved CR, regardless of racial background; however, for those with residual disease, the 2-year survival probabilities were 60.7%, 62.5%, and 51.1% for NHW, HW, and NHB patients, respectively (log-rank P = .010). Our findings revealed differences in chemotherapy response based on gender and race or ethnicity. The CR trends for all racial or ethnic groups increased over time. However, Black patients were found to have worse survival, particularly when residual disease was present. Clinical studies with more underrepresented minorities are needed to verify biological differences in response to neoadjuvant chemotherapy." @default.
• W4377695014 created "2023-05-24" @default.
• W4377695014 creator A5018235125 @default.
• W4377695014 creator A5020308066 @default.
• W4377695014 creator A5046639121 @default.
• W4377695014 creator A5059844177 @default.
• W4377695014 date "2023-08-01" @default.
• W4377695014 modified "2023-09-30" @default.
• W4377695014 title "Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients" @default.
• W4377695014 cites W1964037817 @default.
• W4377695014 cites W1975918912 @default.
• W4377695014 cites W2010464208 @default.
• W4377695014 cites W2024653240 @default.
• W4377695014 cites W2039217307 @default.
• W4377695014 cites W2073175347 @default.
• W4377695014 cites W2078191480 @default.
• W4377695014 cites W2084314714 @default.
• W4377695014 cites W2085682777 @default.
• W4377695014 cites W2103561213 @default.
• W4377695014 cites W2110921920 @default.
• W4377695014 cites W2111817579 @default.
• W4377695014 cites W2138312679 @default.
• W4377695014 cites W2166453367 @default.
• W4377695014 cites W2345559105 @default.
• W4377695014 cites W2644142460 @default.
• W4377695014 cites W2888969259 @default.
• W4377695014 cites W2946882104 @default.
• W4377695014 cites W2991794716 @default.
• W4377695014 cites W3049558133 @default.
• W4377695014 cites W3082322109 @default.
• W4377695014 cites W3117244321 @default.
• W4377695014 doi "https://doi.org/10.1016/j.urology.2023.03.053" @default.
• W4377695014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37230271" @default.
• W4377695014 hasPublicationYear "2023" @default.
• W4377695014 type Work @default.
• W4377695014 citedByCount "0" @default.
• W4377695014 crossrefType "journal-article" @default.
• W4377695014 hasAuthorship W4377695014A5018235125 @default.
• W4377695014 hasAuthorship W4377695014A5020308066 @default.
• W4377695014 hasAuthorship W4377695014A5046639121 @default.
• W4377695014 hasAuthorship W4377695014A5059844177 @default.
• W4377695014 hasConcept C121608353 @default.
• W4377695014 hasConcept C126322002 @default.
• W4377695014 hasConcept C126894567 @default.
• W4377695014 hasConcept C141071460 @default.
• W4377695014 hasConcept C143998085 @default.
• W4377695014 hasConcept C156957248 @default.
• W4377695014 hasConcept C207103383 @default.
• W4377695014 hasConcept C2775910329 @default.
• W4377695014 hasConcept C2776694085 @default.
• W4377695014 hasConcept C2780352672 @default.
• W4377695014 hasConcept C44249647 @default.
• W4377695014 hasConcept C71924100 @default.
• W4377695014 hasConceptScore W4377695014C121608353 @default.
• W4377695014 hasConceptScore W4377695014C126322002 @default.
• W4377695014 hasConceptScore W4377695014C126894567 @default.
• W4377695014 hasConceptScore W4377695014C141071460 @default.
• W4377695014 hasConceptScore W4377695014C143998085 @default.
• W4377695014 hasConceptScore W4377695014C156957248 @default.
• W4377695014 hasConceptScore W4377695014C207103383 @default.
• W4377695014 hasConceptScore W4377695014C2775910329 @default.
• W4377695014 hasConceptScore W4377695014C2776694085 @default.
• W4377695014 hasConceptScore W4377695014C2780352672 @default.
• W4377695014 hasConceptScore W4377695014C44249647 @default.
• W4377695014 hasConceptScore W4377695014C71924100 @default.
• W4377695014 hasLocation W43776950141 @default.
• W4377695014 hasLocation W43776950142 @default.
• W4377695014 hasOpenAccess W4377695014 @default.
• W4377695014 hasPrimaryLocation W43776950141 @default.
• W4377695014 hasRelatedWork W1562998603 @default.
• W4377695014 hasRelatedWork W2022837219 @default.
• W4377695014 hasRelatedWork W2603025253 @default.
• W4377695014 hasRelatedWork W2913013903 @default.
• W4377695014 hasRelatedWork W2921321858 @default.
• W4377695014 hasRelatedWork W2972870493 @default.
• W4377695014 hasRelatedWork W3032049527 @default.
• W4377695014 hasRelatedWork W3111145153 @default.
• W4377695014 hasRelatedWork W3129080622 @default.
• W4377695014 hasRelatedWork W2118673085 @default.
• W4377695014 hasVolume "178" @default.
• W4377695014 isParatext "false" @default.
• W4377695014 isRetracted "false" @default.
• W4377695014 workType "article" @default.